hide-icon
Pattern illustration of DNA helix with a yellow background for the SureSeq NGS product range.

Elevate your MRD strategy with ultra-low frequency variants for AML

Access the full product profile for the SureSeq™ Myeloid MRD Panel - a hybrid-capture NGS panel built for precise, ultra-sensitive detection of low frequency somatic variants in AML, including complex indels and challenging targets like NPM1 and long FLT3-ITDs.

The stakes in MRD detection for AML

Measurable residual disease (MRD) is now recognized as a critical biomarker in AML to help better understand risk stratification, post-treatment surveillance and research into relapse prediction. Yet, most laboratories face limitations in reliably detecting variants at the sub-clonal level — particularly below 0.1% VAF — due to technical constraints of amplicon-based methods and inconsistent informatics pipelines.

The SureSeq Myeloid MRD Panel from OGT address this gap with a rigorously engineered solution for research use, offering:

  • Targeted sequencing of 13 key AML genes and 45 clinically relevant exons
  • Reliable detection of variants down to 0.01% VAF, including long FLT3-ITDs (>300bp)
  • Hybrid-capture chemistry designed to mitigate GC-bias and improve uniformity
  • Seamless variant interpretation via OGT's proprietary bioinformatics platform, Interpret

 

What you'll learn in the product profile

This technical resource explores the molecular architecture, analytical performance and workflow design of the SureSeq Myeloid MRD Panel in detail. Inside, you'll find:

  • A complete gene list and exon-level coverage map
  • Data on detection sensitivity and specificity across variant types
  • Performance metrics for FLT3-ITD detection across a range of lengths
  • Guidance on sample input requirements and library prep protocols
  • Integration options with Interpret software for rapid variant annotation and visualization
  • Application scenarios aligned with ELN MRD Working Group guidelines

 

Why choose a hybrid-capture approach for MRD?

Amplicon-based MRD panels can suffer from allelic dropout, low uniformity and coverage gaps in structurally complex regions — especially for insertion/deletion variants. Hybrid-capture chemistry, by contrast, allows for:

  • Uniform coverage across difficult regions, including high GC-content loci
  • Enhanced detection of longer indels and ITDs, which are critical in understanding AML relapse
  • Reduced need for assay revalidation when expanding to additional targets or adding new samples

OGT's panel architecture has been iteratively optimized to overcome the practical and computational barriers of ultra-deep MRD sequencing, making it an attractive optional for translational research teams aiming for deeper disease surveillance. 

Download the product profile

Designed for precision, built for scalability

Whether your laboratory is focused on MRD assay development or biomarker discovery, the SureSeq Myeloid MRD Panel supports two levels of detection:

  • 0.1% VAF for routine high-throughput MRD research
  • 0.01% VAF for ultra-sensitive, low-burden variant to better understand minimal disease states

This flexibility, paired with automated variant calling and filtering pipelines in Interpret, allows your team to focus on clinical research insight generation rather than troubleshooting sequencing artifacts.

Get the technical overview

If you're seeking an MRD panel that combines analytical rigor with practical deployment — backed by OGT's 25 years of expertise in hybridization-based genomics — this product profile is a must-read.

Download now
Download the product profile